You are here:Home1/News Release2/DATA SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER’S DISEASE
/wordpress/wp-content/uploads/2021/04/logo3.png00chen, chenyan/wordpress/wp-content/uploads/2021/04/logo3.pngchen, chenyan2019-03-29 00:00:002021-03-18 14:44:01DATA SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER’S DISEASE